Investment
Features
FeesSafety
Academy
More
Pluang+

Compare S&P500 ETF (SPY) vs Tilray Brands Inc (TLRY) Price & Performance

S&P500 ETFTrade
Tilray Brands IncTrade

Price performance (Past 24H)

Key statistics

S&P500 ETF vs Tilray Brands Inc — how do they compare? S&P500 ETF trades at $773.01, while Tilray Brands Inc trades at $4.64 (market cap $649.42M). The key difference: S&P500 ETF is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.

SPYTLRY
52-Week High
$773.22$21.00
52-Week Low
$631.99$3.88
Market Cap
$649.42M
Sector
Health
Enterprise Value
$816.55M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

S&P500 ETF

SPY, the SPDR S&P 500 ETF Trust, trades at $773.08 with minimal daily change, reflecting stability near record highs. Technical indicators show a bullish trend with strong moving average signals, though oscillators are neutral and RSI levels suggest overbought conditions. The ETF remains a core holding for broad U.S. equity exposure, with a dividend scheduled for July 2026. Market sentiment is mixed, balancing optimism from AI-driven gains against concerns over elevated valuations.

The outlook for SPY hinges on sustained earnings growth and macroeconomic factors, with upside potential if corporate profits meet expectations. Risks include high valuation multiples, potential interest rate shifts, and geopolitical tensions. Institutional analysts monitor inflation data and earnings revisions for directional cues, with the ETF's low expense ratio and liquidity supporting its appeal for long-term investors.

Tilray Brands Inc

TLRY trades at $4.71, up 6.56% today, with a bullish technical signal from moving averages but mixed oscillators. Revenue grew to $821M in 2025, yet the company posted a net loss of -$2.19B, reflecting profitability challenges. Recent news highlights growth initiatives, including a partnership with Wolverhampton Wanderers and a new THC pouch launch. The stock remains volatile, with a low P/S of 0.58 and P/B of 0.4, suggesting potential undervaluation amid ongoing losses.

Outlook is cautious; TLRY's path to profitability hinges on revenue growth and cost management. Risks include persistent losses, high debt, and regulatory uncertainty. Analyst consensus is mixed, with 25% buy ratings but 65% hold, indicating skepticism. Investors should weigh growth potential against financial instability and market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About S&P500 ETF

The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on SPY

About Tilray Brands Inc

Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.

Read more on TLRY